QPPV.COM KNOWLEDGE ASSESSMENT

Golimumab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Golimumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An inspector reviews an organisation's golimumab pharmacovigilance system. Which capability would most directly demonstrate effective translation of class knowledge into product-level surveillance?
Question 2 of 10 Which statement best describes the significance of golimumab's fully human antibody format?
Question 3 of 10 Which interpretation of new dyspnoea and oedema in a patient receiving golimumab is most appropriate?
Question 4 of 10 Why must jurisdiction and route be retained in golimumab exposure records?
Question 5 of 10 What best explains the central pharmacovigilance trade-off associated with TNF blockade?
Question 6 of 10 Why should spontaneous reports of infection not be converted directly into an infection incidence rate?
Question 7 of 10 A patient with ulcerative colitis reports worsening stool frequency during golimumab therapy. Which evaluation best assesses possible loss of efficacy?
Question 8 of 10 Why should product and batch information be retained for golimumab biological traceability?
Question 9 of 10 A patient receiving golimumab has a positive tuberculosis screening test but no clinical or microbiological evidence of active disease. How should the case be represented?
Question 10 of 10 Which description best captures golimumab's pharmacological classification?

Select an answer to continue.

QPPV.com